SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-009984
Filing Date
2023-02-02
Accepted
2023-02-02 17:15:16
Documents
12
Period of Report
2023-01-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm235341d1_8k.htm   iXBRL 8-K 29950
  Complete submission text file 0001104659-23-009984.txt   202986

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA icpt-20230127.xsd EX-101.SCH 3054
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE icpt-20230127_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE icpt-20230127_pre.xml EX-101.PRE 22609
6 EXTRACTED XBRL INSTANCE DOCUMENT tm235341d1_8k_htm.xml XML 3498
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35668 | Film No.: 23582218
SIC: 2834 Pharmaceutical Preparations